Glass House Brands (GLAS) Revenue (2020 - 2026)

Glass House Brands (GLAS) posted quarterly Revenue of $40.5 million for Q1 2026, up 4.27% quarter-over-quarter from $38.9 million in Q4 2025.

Glass House Brands (GLAS) Revenue (2020 - 2026) Analysis & Trends

Glass House Brands (GLAS) has reported Revenue for 7 consecutive years, with $40.5 million the latest figure, recorded in Q1 2026.

In Q1 2026, Revenue changed N/A year-over-year to $40.5 million; the TTM figure through Mar 2026 stood at $177.7 million (changed N/A YoY), while the FY2025 annual figure was $182.0 million, down 9.41% from the prior year.
Revenue climbed to $40.5 million in Q1 2026 per GLAS's latest filing, from $38.9 million in the prior quarter.
Across five years, Revenue topped out at $59.9 million in Q2 2025 and bottomed at $14.0 million in Q1 2022.
Historically, Revenue has averaged $36.5 million across 5 years, with a median of $38.6 million in 2025.
Annual changes were most pronounced in 2022 — Revenue tumbled 100.0% — and 2023, when it jumped 171.14%.
Glass House Brands' Revenue stood at $29.9 million in 2022, then soared by 49.2% to $44.7 million in 2023, then advanced by 20.76% to $53.9 million in 2024, then slipped by 27.96% to $38.9 million in 2025, then rose by 4.27% to $40.5 million in 2026.
Business Quant data shows GLAS's Revenue at $40.5 million in Q1 2026, $38.9 million in Q4 2025, and $38.4 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Haleon	86.50 Bn	85.53 Bn	-	-
2	Teva Pharmaceutical Industries	42.71 Bn	39.05 Bn	2.15 Bn	4.14 Bn
3	Zoetis	30.86 Bn	29.18 Bn	1.80 Bn	2.47 Bn
4	Takeda Pharmaceutical	28.50 Bn	22.70 Bn	5.10 Bn	7.65 Bn
5	United Therapeutics	22.06 Bn	19.40 Bn	683.80 Mn	783.30 Mn
6	Viatris	18.84 Bn	17.95 Bn	1.46 Bn	3.76 Bn
7	Neurocrine Biosciences	15.55 Bn	15.16 Bn	935.80 Mn	959.00 Mn
8	Vireo Growth	11.86 Bn	11.71 Bn	59.30 Mn	106.20 Mn
9	Elanco Animal Health	11.77 Bn	11.24 Bn	798.00 Mn	1.37 Bn
10	Glass House Brands	822.44 Mn	794.51 Mn	10.02 Mn	40.52 Mn

Download Data